Orally active isoxazoline glycoprotein IIb/IIIa antagonists with extended duration of action

Journal of Medicinal Chemistry

Volumn 42, Issue 7, 1999, Pages 1178-1192

  Olson, Richard E ^a   Sielecki, Thais M ^a   Wityak, John ^a   Pinto, Donald J ^a   Batt, Douglas G ^a   Frietze, William E ^a   Liu, Jie ^a   Tobin, A Ewa ^a   Orwat, Michael J ^a   Di Meo, Susan V ^a   Houghton, Gregory C ^a   Lalka, George K ^a   Mousa, Shaker A ^a   Racanelli, Adrienne L ^a   Hausner, Elizabeth A ^a   Kapil, Ram P ^a   Rabel, Shelley R ^a   Thoolen, Martin J ^a   Reilly, Thomas M ^a   Anderson, Paul S ^a   Wexler, Ruth R ^a   more..

^a DUPONT COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [[3 [4 (AMINOIMINOMETHYL)PHENYL] 4,5 DIHYDRO 5 ISOXAZOLYL]ACETAMIDO] N [(3,5 DIMETHYL 4 ISOXAZOLYL)SULFONYL]ALANINE; FIBRINOGEN RECEPTOR ANTAGONIST; ISOXAZOLINE DERIVATIVE; ROXIFIBAN;

ANIMAL EXPERIMENT; ARTICLE; DOG; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION INHIBITION;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CRYSTALLOGRAPHY, X-RAY; DOGS; HUMANS; INJECTIONS, INTRAVENOUS; ISOXAZOLES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; TIME FACTORS;

EID: 0033535522     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980348t     Document Type: Article

References (49)

1. Muller, T. H.; Binder, K.; Guth, B. D. Pharmacology of Current and Future Antithrombotic Therapies. Cardiol. Clin. 1994, 12, 411-442.
2. Schafer, A. I. Antiplatelet Therapy. Am. J. Med. 1996, 101, 199-209.
3. 3). Advances in Molecular and Cell Biology; JAI Press: Greenwich, CT, 1997; Vol. 18, pp 67-107.
4. Hawiger, J.; Kloczewiak, M.; Bednarek, M.; Timmons, S. Platelet Receptor Recognition Domain on alpha Chain of Human Fibrinogen: Structure-Function Analysis. Biochemistry 1989, 28, 2909-2914.
5. Farrell, D. H.; Thiagarajan, P.; Chung, D. W.; Davie, E. W. Role of Fibrinogen α and γ Chain Sites in Platelet Aggregation. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 10729-10732.
6. 3 (GPIIb/IIIa): A Target for Novel Anti-platelet Drugs. Pharmacol. Rev. Commun. 1996, 8, 257-265.
7. Samanen, J. GPIIb/IIIa Antagonists. Annu. Rep. Med. Chem. 1996, 31, 91-100.
8. 3 as an antithrombotic target. Perspect. Drug Discov. Des. 1993, 1, 537-548.
9. Kereiakes, D. J.; Kleiman, N.; Ferguson, J. J.; Runyon, J. P.; Broderick, T. M.; Higby, N. A.; Martin, L. H.; Hantsbarger, G.; Mcdonald, S.; Anders, R. J. Sustained platelet glycoprotein IIb/ IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment. Circulation 1997, 96, 1117-1121.
10. Nicholson, N.; Taite, B.; Panzer-Knodle, S.; Salyers, A.; Haas, N.; Szalony, J.; Frederick, L.; Suleymanov, O.; King, L.; Page, J.; Feigen, L. Biological activity of orbofiban, an orally active inhibitor of glycoprotein IIb/IIIa and platelet aggregation. Thrombosis Haemostasis 1997, 2719 (Suppl.), 666.
11. Cannon, C. P.; McCabe, C. H.; Borzak, S.; Henry, T. D.; Tischler, M. D.; Mueller, H. S.; Feldman, R.; Palmeri, S. T.; Ault, K.; Hamilton, S. A.; Rothman, J. M.; Novotny, W. F.; Braunwald, E. For the TIMI 12 Investigators. Randomized Trial of an Oral Platelet Glycoprotein IIb/IIIa Antagonist, Sibrafiban, in Patients After an Acute Coronary Syndrome. Results of the TIMI 12 Trial. Circulation 1998, 97, 340-349.
12. Muller, T. H.; Weisenberger, H.; Brickl, R.; Narjes, H.; Himmelsbach, F.; Krause, J. Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban. Circulation 1997, 96, 1130-1138.
13. Wityak J. Atherosclerosis ID Res. Alerts 1997, 2, 185-197.
14. Lefkovits, J.; Topol, E. J. Platelet glycoprotein IIb/IIIa receptor antagonists in coronary artery disease. Eur. Heart J. 1996, 17, 9-18.
15. Wexler, R. R. Antiplatelet Agents. In Proceedings, XIVth International Symposium on Medicinal Chemistry; Awouters, F., Ed.; Elsevier Science B.V.: Amsterdam, 1997; pp 511-535.
16. (a) Coller, B. S.; Anderson, K. M.; Weisman, H. F. Haemostasis 1986, 26 (Suppl. 4), 285-293.
17. (b) Nurden, A. T. New Thoughts on Strategies for Modulating Platelet Function Through the Inhibition of Surface Receptors. Haemostasis 1996, 26 (Suppl. 4), 78-88.
18. (c) Timmis, G. C.; Khurana, S. Advances in Antiplatelet Therapy in Coronary Artery Disease: Importance of the Platelet GPIIb/IIIa Receptor. J. Intervent. Cardiol. 1997, 10, 327-333.
19. Mousa, S. A.; Bennett, J. A. Platelets in health and disease: platelet GPIIb-IIIa structure and function: recent advances in antiplatelet therapy. Drugs Future 1996, 21, 1141-1154.
20. Reilly, T. M.; Mousa, S. A.; Racanelli, A. L. New antiplatelet drugs. Emerging Drugs 1997, 2, 73-91.
21. Wityak, J.; Sielecki, T. M.; Pinto, D. J.; Sze, J. Y.; Liu, J.; Tobin, A. E.; Wang, S.; Jiang, B.; Emmett, G.; Ma, P.; Mousa, S. A.; Olson, R. E.; Wexler, R. R. The Discovery of Potent Isoxazoline Glycoprotein IIb/IIIa Receptor Antagonists. J. Med. Chem. 1997, 40, 50-60.
22. Xue, C.-B.; Wityak, J.; Sielecki, T. M.; Pinto, D. J.; Batt, D. G.; Cain, G. A.; Sworin, M.; Rockwell, A. L.; Roderick, J. J.; Wang, S.; Orwat, M. J.; Frietze, W. E.; Bostrom, L. L.; Liu, J.; Higley, C. A.; Rankin, F. W.; Tobin, A. E.; Emmett, G.; Lalka, G. K.; Sze, J. Y.; Di Meo, S. V.; Mousa, S. A.; Thoolen, M. J.; Racanelli, A. L.; Hausner, E. A.; Reilly, T. M.; DeGrado, W. F.; Wexler, R. R.; Olson, R. E. Discovery of an Orally Active Series of Glycoprotein IIb/IIIa Antagonists. J. Med. Chem. 1997, 40, 2064-2084.
23. (a) Mousa, S. A.; Bozarth, J.; Forsythe, M.; Xue, C.-B.; Wityak, J.; Olson, R.; Thoolen, M.; Reilly, T. Discovery of Novel Non-peptide Antiplatelet GPIIb/IIIa Receptor Antagonist, DMP 754: Receptor Binding Affinity and Specificity. Circulation 1996, 94, I-513, 3006.
24. (b) Mousa, S. A.; Forsythe, M.; Lorelli, W.; Bozarth, J.; Xue, C.-B.; Wityak, J.; Sielecki, T. M.; Olson, R. E.; DeGrado, W.; Kapil, R.; Hussein, M.; Wexler, R.; Thoolen, M. J.; Reilly, T. M. Novel nonpeptide antiplatelet glycoprotein IIb/ IIIa receptor antagonist, DMP754: receptor binding affinity and specificity. Coron. Art. Dis. 1996, 7, 767-774.
25. Mousa, S. A.; Bozarth, J.; Forsythe, M.; Xue, C.-B.; Wityak, J.; Olson, R.; Thoolen, M.; Reilly, T. Discovery of Novel Non-peptide Antiplatelet GPIIb/IIIa Receptor Antagonist, DMP 754: Comparitive Platelet Binding Affinity Profiles with DMP 728 and c7E3. Thrombosis Hemostasis 1997, 2707 (Suppl.), 663.
26. Xue, C.-B.; Rafalski, M.; Roderick, J.; Eyermann, C. J.; Mousa, S.; Olson, R. E.; DeGrado, W. F. Design, Synthesis and In Vitro Activities of a Series of Benzimidazole/Benzoxazole Glycoprotein IIb/IIIa Inhibitors. Bioorg. Med. Chem. Lett. 1996, 6, 339-344.
27. Xue, C.-B.; Roderick, J.; Jackson, S.; Rafalski, M.; Rockwell, A.; Mousa, S.; Olson, R. E.; DeGrado, W. F. Design, Synthesis and In Vitro Activities of Benzamide-Core Glycoprotein IIb/IIIa Antagonists: 2,3-Diaminopropionic Acid Derivatives as Surrogates of Aspartic Acid. Bioorg. Med. Chem. 1997, 5, 693-705.
28. Egbertson, M. S.; Bednar, B.; Bednar, R. A.; Hartman, G. D.; Gould, R. J.; Lynch, R. J.; Vassallo, L. M.; Young, S. D. Non-peptide Glycoprotein IIb/IIIa Inhibitors. 9. Centrally Constrained Alpha-Sulfonamides Are Useful Tools for Exploring Platelet Receptor Function. Bioorg. Med. Chem. Lett. 1996, 6, 1415-1420.
29. Halczenko, W.; Cook, J. J.; Holahan, M. A.; Sitko, G. R.; Stranieri, M. T.; Zhang, G.; Lynch, R. J.; Lynch, J. J., Jr.; Gould, R. J.; Hartman, G. D. Nonpeptide Glycoprotein IIb/IIIa Inhibitors. 12. Potent and Orally Active Centrally Constrained Thieno[2,3-c]pyridones. Bioorg. Med. Chem. Lett. 1996, 6, 2771-2776.
30. Askew, B. C.; Bednar, R. A.; Bednar, B.; Claremon, D. A.; Cook, J. J.; McIntyre, C. J.; Hunt, C. A.; Gould, R. J.; Lynch, R. J.; Lynch, J. J., Jr.; Gaul, S. L.; Stranieri, M. T.; Sitko, G. R.; Holahan, M. A.; Glass, J. D.; Hamill, T.; Gorham, L. M.; Prueksaritanont, T.; Baldwin, J. J.; Hartman, G. D. Non-Peptide Glycoprotein IIb/IIIa Inhibitors. 17. Design and Synthesis of Orally Active, Long-Acting Non-Peptide Fibrinogen Receptor Antagonists. J. Med. Chem. 1997, 40, 1779-1788.
31. Prugh, J. D.; Gould, R. J.; Lynch, R. J.; Zhang, G.; Cook, J. J.; Holahan, M. A.; Stranieri, M. T.; Sitko, G. R.; Gaul, S. L.; Bednar, R. A.; Bednar, B.; Hartman, G. D. Nonpeptide GPIIb/ IIa Inhibitors. 16. Thieno[2,3-b]thiophene α-Sulfonamides are Potent Inhibitors of Platelet Aggregation. Bioorg. Med. Chem. Lett. 1997, 7, 865-870.
32. Brashear, K. M.; Cook, J. J.; Bednar, B.; Bednar, R. A.; Gould, R. J.; Halczenko, W.; Holahan, M. A.; Lynch, R. J.; Hartman, G. D.; Hutchinson, J. H. Nonpeptide Glycoprotein IIb/IIIa Inhibitors: 18. Indole Alpha-Sulfonamide Acids are Potent Inhibitors of Platelet Aggregation. Bioorg. Med. Chem. Lett. 1997, 7, 2793-2798.
33. Cook, J. J.; Sitko, G. R.; Holahan, M. A.; Stranieri, M. T.; Glass, J. D.; Askew, B. C.; McIntyre, C. J.; Claremon, D. A.; Baldwin, J. J.; Hartman, G. D.; Gould, R. J.; Lynch, J. J., Jr. Nonpeptide Glycoprotein IIb/IIIa Inhibitors. 15. Antithrombotic Efficacy of L-738,167, a Long-Acting GPIIb/IIIa Antagonist, Correlates With Inhibition of Adenosine Diphosphate-Induced Platelet Aggregation But Not With Bleeding Time Prolongation. J. Pharmacol. Exp. Ther. 1997, 287, 677-689.
34. Su, T.; Naughton, M. A.; Smyth, M. S.; Rose, J. W.; Arfsten, A. E.; McCowan, J. R.; Jakubowski, J. A.; Wyss, V. L.; Ruterbories, K. J.; Sall, D. J.; Scarborough, R. M. Fibrinogen Receptor (GPIIb-IIIa) Antagonists Derived from 5,6-Bicyclic Templates. Amidinoindoles, Amidinoindazoles, and Amidinobenzofurans Containing the N-α-Sulfonamide Carboxylic Acid Function as Potent Platelet Aggregation Inhibitors. J. Med. Chem. 1997, 40, 4308-4318.
35. Kloek, J. A.; Leschinsky, K. L. Improved synthesis of sulfamoyl chlorides. J. Org. Chem. 1976, 41, 4028-4029.
36. Audrieth, L. F.; Sveda, M. Preparation and properties of some N-substituted sulfamic acids. J. Org. Chem. 1944, 9, 89-101.
37. The isoxazolinylacetamides 12-45 of the present study are designated "a" when racemic at the isoxazoline C5 center and (S) at the diaminopropionate (DAP) center; the (A)-C5,(S)-DAP isomere "b"; the (S)-C5,(S)-DAP isomers "c"; the (R)-C5,(R)-DAP isomers "d"; and the (S)-C5,(A)-DAP isomers "e".
38. Mokotoff, M.; Logue, L. W. Potential inhibitors of asparagine biosynthesis. 5. electrophilic amide analogues of (S)-2,3-diaminopropionic acid. J. Med. Chem. 1981, 24, 554-559.
39. For in vitro assay protocols, see: Mousa, S. A.; Bozarth, J. M.; Forsythe, M. S.; Lorelli, W.; Ramachandran, N.; Jackson, S.; De Grado, W. F.; Reilly, T. M. Antiplatelet Efficacy and Specificity of DMP 728, A Novel Platelet GPIIb/IIIa Receptor Antagonist. Cardiology 1993, 83, 374-382.
40. Bednar, B.; Cunningham, M. E.; McQueney, P. A.; Egbertson, M. S.; Askew, B. C.; Bednar, R. A.; Hartman, G. D.; Gould, R. J. Flow Cytometric Measurement of Kinetic and Equilibrium Binding Parameters of Arginine-Glycine-Aspartic Acid Ligands in Binding to Glycoprotein IIb/IIIa on Platelets. Cytometry 1997, 28, 58-65.
41. Prueksaritanont, T.; Gorham, L. M.; Naue, J. A.; Hamill, T. G.; Askew, B. C.; Vyas, K. P. Disposition of L-738,167, A Potent and Long Acting Fibrinogen Receptor Antagonist in Dogs: Dose-dependent Pharmacokinetics. Drug Metab. Dispos. 1997, 25, 355-361.
42. Bednar, R.; Gaul, S. L.; Cook, J. J.; Askew, B. C.; Hartman, G. D.; Gould, R. J.; Bednar, B. Novel Mechanism for Long Acting GPIIb/IIIa Antagonists. Circulation 1996, 94, I-98, 0568.
43. Belz, G. G.; Kirch, W.; Kleinbloesem, C. H. Angiotensin-Converting Enzyme Inhibitors. Relationship Between Pharmacodynamics and Pharmacokinetics. Clin. Pharmacokinet. 1988, 15, 295-318.
44. Colburn, W. A.; Jack, M. L. Relationships Between CSF Drug Concentrations, Receptor Binding Characteristics, and Pharmacokinetic and Pharmacodynamic Properties of Selected 1,4-Substituted Benzodiazepines. Clin. Pharmacokinet. 1987, 13, 179-190.
45. Mousa, S.; Forsythe, M.; Bozarth, J.; Youssef, A.; Wityak, J.; Olson, R.; Sielecki, T. XV454, A novel non-peptide antiplatelet agent with comparable platelet alphaIIb beta3 binding kinetics to c7E3 and long lasting antiplatelet efficacy after single intravenous or oral administration in nonhuman primates. Circulation 1997, 96, I-168, 928.
46. 3 Binding Kinetics to c7E3. Submitted to J. Cardiovasc. Pharmacol. 1998.
47. Mousa, S. A.; Olson, R. E.; Bozarth, J. M.; Lorelli, W.; Forsythe, M. S.; Racanelli, A.; Gibbs, S.; Schlingman, K.; Bozarth, T.; Kapil, R.; Wityak, J.; Sielecki, T. M.; Wexler, R. R.; Thoolen, M. J.; Slee, A.; Reilly, T. M.; Anderson, P. S.; Friedman, P. A. Oral Antiplatelet Efficacy and Specificity of a Novel Non-Peptide Platelet GPIIb/IIIa Receptor Antagonist, DMP 802. J. Cardiovasc. Pharmacol. 1998, 32, 169-176.
48. Mokotoff, M.; Logue, L. W. Potential Inhibitors of L-Asparagine Biosynthesis. 5. Electrophilic Amide Analogues of (S)-2,3-Diaminopropionic Acid. J. Med. Chem. 1981, 24, 554-559.
49. Matier, W. L.; Comer, W. T.; Deitchman, D. Sulfamoyl azides, Hydrolysis rates and hypotensive activity. J. Med. Chem. 1972, 15, 538-541.